Slide sets from talks and workshops

The following selccted slide sets for i-Base community workshops and other talks were produced by i-Base advocates. These are free to use for any non-commercial application.

When third-party slides are used these remain the copyright of the original author.

Most talks are by Simon Collins, unless specified otherwise.

Community perspectives of new research

Talk from June 2019 as part of HMRG European HIV Seminar held in Dublin.

The talk looked at advances in treatment over three decades and yet new drugs are still approved with limited data in women, during pregnancy and with TB drugs. Also the delay in access for children.

HMRG 2019 –  PDF slides (7 MB)

CROI 2019 feedback

Set of approximately 60 slides compiled from key studies presented at the recent CROI 2019 medical conference in Seattle.

This presentation was to the UK-Community Advisory Board (UK-CAB) meeting on 6 April 2019.

CROI 2019 feedback UK-CAB – PDF slides (5.6 MB)

Is rapid ART right for all?

Talk given on the last day of the 25th BHIVA conference held in Bournemouth (BHIVA 2019).

The talk includes reports from two clinics where people are offered ART when they have their first appointment after diagnosis – often on the same day. All other services and tests and services are reorganised to enable this.

Webcast link – (At approx 1hr2mins if doesn’t load automatically)

Rapid ART for all? – PDF slides. (3 MB)

Rapid ART for all? – notes – PDF with notes. (3 MB)

Ethical issues and informed consent in HIV cure research studies: EATG workshop, Glasgow 2018

A talk looking at a common disconnect between researchers and participants in HIV cure-related studies.

More researchers except no or little clinical benefit. Many participants still think they had a slight or more significant hope that they might be cured.

ECAB cure – Glasgow 2018 – PDF (100 Mb)

20th National HIV Nurses Association (NHIVNA) conference, July, Brighton

Evidence for U=U: the PARTNER study and Prevention Access Campaign

Talk as part of the pre-conference workshop about the evidence over twenty years for the U=U campaign.

This included the London version:
A=A: Ain’t no viral load, ain’t no risk of HIV.

NHIVNA U=U talk 27 June 2018  (PDF – (7.2 MB)

NHIVNA U=U talk with NOTES (PDF – 3.4 MB)

4th National Conference of People Living with HIV (October 2017)

Treatment update for London HIV positive conference.

Topics cover evidence for U=U and treatment updates for new drugs.

This talk was largely based on the talks given at the HIV Scotland conference below.

UK HIV+ conference 2017 Treatment update  (PDF – 8.5 MB)

Paediatric HIV pipeline drugs (October 2017)

Talk on pipeline HIV drugs for children given by Polly Clayden to a closed meeting of the IMPAACT trial network.

This is a focus on the paediatric pipeline, that usually takes several years (at least) after a drug is approved for adults.

This also usually occurs in age bands – first adolescents, then children and finally infants and babies. Many HIV drugs, however, are never approved for the youngest children.

Paediatric ART pipeline IMPAACT – (PDF – 950 Kb)

slides cover graphic

Positive Peoples Forum – HIV Scotland (July 2017)

Two talks for the annual HIV positive conference held in Glasgow this year.

Undetectable = uninfectious (U=U) – PDF (3.3 MB)

A talk about HIV treatment as prevention (TasP) that reviews the evidence for why so many doctors, scientist and community groups say that an undetectable viral load means you cannot transmit HIV to partners.

This was included as an idea in US guidelines in 1998 and has been supported by accumulating evidence from different studies over the last 20 years.

PPF talk slide cover 2017 2017 Treatment update – PDF (4.0 MB)

Short update about new HIV meds in development, drug pricing in the UK, cure research and PrEP.

This includes the HIV lifecycle to show how current HIV drugs work at different sites and the new targets for the most promising upcoming drugs.

A couple of slides are included on drug pricing in the UK and how generics affect this.

CROI 2017 feedback UK-CAB graphicCROI 2017: feedback to UK-CAB (April 2017)

Short talk to feedback key studies for the UK-CAB.

Mainly to cover cure research, new drugs and treatment strategies.

CROI 2017 feedback UK-CAB – PDF (5 MB)

Review of i-Base treatment information services (April 2016)

Talk given by Robin Jakob to BHIVA conference about the phoneline and Q&A services.


Reference: HIV treatment information and advocacy 2014/15: continued demand for community support services. R Jakob, R Trevelion, J Dunworth, M Sachikonye and S Collins. 22nd Annual BHIVA Conference, 19-22 April 2016, Manchester. Oral abstract O5. HIV Medicine, 17 (Suppl. 1), 3–13. HIV Medicine 17, 4, 2016.
Treatment advocacy – 2014-15 – Robin Jakob – PDF slides.

HIV testing: who, how and why? (September 2015)

Martin Fisher talk graphicTalk on HIV testing as part of the launch for the Martin Fisher Foundation.

Martin was one of the key doctors whose skills, energy and determination over the last 20 years were responsible for ensuring that HIV positive people in the UK received such high standards of care.

He was also a scientist and researcher, activist and friend. Martin was an incredibly kind, passionate, popular and modest man and his partner Adrian together with his family, friends and colleagues have launched this foundation to celebrate and continue his work.

HIV Testing Martin Fisher foundation talk – PowerPoint (2 Mb) HIV testing MFF – PDF (2 Mb)

Watch webcast on Vimeo.

2015 treatment update: good time for a change (September 2015)

UK HIV+ conference talk graphic 2015Talk to UK Conference of People Living with HIV on dramatic developments in treatment.

  • Impact of START study on BHIVA and WHO guidelines.
  • Absolute and relative benefits from earlier treatment.
  • TasP and PrEP.
  • Immune inflammation.
  • ART in acute infection and cure research.

UK HIV conference 2015 – PDF (900 Kb) UK PWA conference 2015 – PowerPoint (1.1 Mb)

START study results and new BHIVA guidelines – UK-CAB (July 2015)

CAB july 2015 coverThis talk to the UK-CAB went covered:

  • The question of when to start HIV treatment.
  • The differences between observational studies and randomised controlled trials (RCTs).
  • Design of the START study.
  • Top-line results and implications.
  • Draft UK BHIVA treatment guidelines: key changes and how to comment.

PowerPoint slides UK-CAB july 2015 (250 Kb) PDF file UK-CAB july 2015 (160 Kb)

Treatment Q&A at Bloomsbury Clinic (May 2015)

Bloomsbury talk graphicThis talk to an HIV positive group at a central London clinic included a discussion about generic HIV meds.

The talk included a doctor, a study researcher and an advocate.

PowerPoint – (4.5 MB) PDF – (4.8 Mb)

Are patient information leaflets for research studies too difficult to read? (April 2015)

BHIVA slides graphicThis talk was for the British HIV Association spring conference.

It was a small study lead by advocates at i-Base and was selected by the conference for an oral presentation (Abstract O_4).

The study calculated readability scores from nine ongoing studies and compared them to two community-produced examples.

The presentation was also awarded one of two prizes from BHIVA and Mediscript for the best oral or poster research on social science or community-based work.

Wednesday_1530_Oral_Session_clip_4.mp4 (Webcast from BHIVA website)

PowerPoint slides (1.6 Mb)  PDF version – (1.1 Mb)

Community feedback from CROI 2015 – UK-CAB (April 2015)

CROI feedback talk graphicFeedback to UK-CAB meeting based on slide sets produced by the BHIVA CROI working group on prevention and new drugs.

  • The PROUD and IPERGAY studies
  • Other PrEP studies including PARTNERS PrEP and FACTS 001.
  • TAF – new version of TDF
  • Attachement inhibitors and maturation inhibitors.

PowerPoint file – (5.3 Mb)  PDF slides file – PDF (3MB)  6-up handout – PDF (1.2 Mb)

Seminar on PrEP and chemsex – Copenhagen (March 2015)

PrEP QoL slide graphic

Talk about recent and current experiences in the UK about PrEP.

This included community involvement in the PROUD study, the IDMC recommendation in October 2014 to offer PrEP to all participants, and community responses since.

Plus a short update on PrEP studies at CROI 2015.

The meeting was organised by the Danish HIV organisation AIDSFONDNET and included HIV positive and HIV negative community activists and health professionals.

PrEP talk copenhagen – PDF (5.9 Mb)

Imperial College BSc Global Health course (Jan 2015)

jan2015 talk graphicShort talk to fourth-year medical students about HIV activism from a person perspective. It mainly uses picture to compliment another lecture in the course on the history of HIV activism.

PDF file (1.5 MB)

Please email for higher resolution or PowerPoint files.

Imperial College medical students (Dec 2014)

Talk to 300 first-year medical students at Imperial College about role of patient/doctor partnership and communication. Also how treatment literacy can support people to take an active role in their healthcare.

Includes references to early US activism, including the Denver Principles (1983) and personal perspectives as a patient activist in the UK.

PowerPoint with notes (6.1 MB) PDF file (6.1 MB) – please email for higher resolution files.

PrEP: a community perspective (November 2014)

Friends slide PrEP

Talk about PrEP (Pre-Exposure Prophylaxis) from the HIV Conference in Glasgow. The talk looks at the history of PrEP and a few myths.

Although optimal use will be in situations where HIV risk is high, PrEP – just like TasP (Treatment as Prevention) – may help reduce stigma against HIV.

It may also help improve quality of life by reducing fear and anxiety about HIV.

Powerpoint with notes (7.5 MB) PDF file (2.4 MB) PrEP talk slide notes Word.doc (50 Kb)

This talk is available as a webcast.

Collins S. Journal of the International AIDS Society 2014, 17(Suppl 3):19522 Conference abstract.

PHI talk graphic

Option to use ART in early HIV infection (Oct 2014)

Talk about the importance for people who are diagnosed within 6 months of infection to be given the choice of using ART, irrespective of CD4 count. This short window may be very different to starting at any time after 6 months and yet many people do not have this discussion. Talk for BHIVA autumn conference 2014.

BHIVA 2014 early ART talk – PDF (200 Kb) BHIVA 2014 early ART talk – PowerPoint (400 Kb)

Science intro graphic

UK-CAB advocates training (Sep 2014)

  1. Introduction to science and importance of evidence-based medicine. Powerpoint slides (1 MB) and PDF (1.1 MB)
  2. Tips for writing patient-friendly information – Powerpoint slides (200 Kb) and PDF file (280 Kb)

Two talks for the this 4-day UK-CAB advocacy training.

Health service constraints on HIV care – the research agenda: a UK perspective (March 2014)

Short presentation to European CHAIN research network to mark the completion of this five-year research programme. PDF and PowerPoint (500 Mb)

Community views on long-acting ARVs (March 2014)

Short presentation to US NIH mixed stakeholder meeting (researchers, regulators, industry and community) on the development of long-acting HIV meds, especially injections. PowerPoint (600 Mb) and PDF (400 Mb),

Talk to medical students (Nov 2013)

Talk to 300 first-year medical students at Imperial College about how HIV activism has affected patent involvement in care. Powerpoint (with notes) (6 MB) and  PDF (slides only) (6 MB)

Hot topics in HIV treatment (Oct 2013)

Talk to UK HIV positive conference on six important topics that could change HIV care in the next year: Access to ARVs and generics in the new NHS/When to start and why guidelines differ… /Treatment as Prevention/New HIV drugs: Stribild, dolutegravir, TAF, GSK-744/Hepatitis C and sexual transmission/Hepatitis C: new HCV drugs (DAAs) – PDF (98 Kb)

UK-CAB advocates training (Oct 2013)

  1. Introduction to science and importance of evidence-based medicine. Powerpoint slides (1 MB) and PDF (1.1 MB)
  2. Tips for writing patient-friendly information – Powerpoint slides (200 Kb) and PDF file (280 Kb)

HIV and cancer (April 2013)

HIV and cancer slides coverIntroduction to HIV and cancer – talk to UK-CAB.

This talk highlights that it is mainly because HIV treatment is so effective that we are living long enough for cancer to be a complication. For nearly all cancers, older age is one of the key risk factors.

HIV makes the risk of some cancers slightly higher than the general population. These risks are still relatively unlikely events. To reduce these risks, the same lifestyle changes as the general population are just as important for HIV positive people – perhaps more so.

From a personal perspective, managing a cancer diagnosis is serious and meant you have to make your health a main priority to give yourself the best chance. This gives many people a new chance to make the most of their time, irrespective of the outcome.

PowerPoint (135 Kb) PDF (70 Kb)

HIV cure research: pieces in the puzzle (January 2013)

cure research slides graphicOverview of cure research – talk to UK-CAB.

This non technical talk explains the science behind four key approaches to cure research. This is a puzzle and all four are likely to be needed on the way to finding a cure.

The context includes the context for the research, background on why a cure is difficult and ethical issues related to this research.

PowerPoint (2.5 Mb) PDF (3.4 Mb)

Budget issues affecting treatment choice: the London tender process (November 2012)

glasgow talk graphicTalk given at the Glasgow Congress on HIV Drug Therapy as part of the community programme on HIV services in Europe. This focusses on the London therapeutic tender for HIV drugs that saved £5 million with reducing quality of services or range or drugs that are available.

PowerPoint slides November 2012 – (180 Kb) PDF file (140 Kb) Text notes (Word.docx)

This talk is available as a webcast on the conference website: MAC webcast – PC webcast.

IAS July 2012 – Washington

Feedback from the International AIDS conference held in Washington in July 2012:  PDF (400 Kb) PowerPoint (975 Kb)

Slides for a talk at a feedback meeting organised by the UK Consortium.

CROI February 2010 – San Francisco

A talk on community perspectives from the Retroviruses Conference (CROI) given to the feedback meetings organised by BHIVA.

Treatment Action Campaign

Showing the different measures for CD4 counts and viral load including millilitre, microlitre, mL, mm3, μL). Also, showing why you still have many millions of CD4 cells in your body even at very low CD4 counts.

Set of graphs showing how drugs are absorbed and then leave your body and how missing a dose leads to low levels and the risk of resistance. Explains the pharmocology terms including Cmax, Tmax, half-life (T½), MEC (minimum effective concentration) etc.

Set of 12 slides listing important studies and issues from 2010.

Trials and Research

What is a DSMB, why should community members be involved, what is required. Training for the European Community Advisory Board.

UK-CAB presentations

Slides from all UK-CAB meetings are posted online as an open access training resource.

Conference slides (archive)

  • Retrovirus conference (CROI) 2008: ARVs – PDF
  • IAS conference 2007 feedback (Sydney) – PDF,
  • IAS conference 2006 feedback (Toronto) – PowerPoint
  • Drug development timelines (2006) TAC – PDF, PowerPoint
  • Importance of treatment literacy (2006) Moscow – PowerPoint
  • Community outreach in national and international trials (2006) MRC – PowerPoint
  • Life experience: self empowerment through treatment advocacy (2005) Taiwan – PowerPoint